1. Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae
- Author
-
Pacios, Olga, Fernández-García, Laura, Bleriot, Ines, Blasco, Lucía, González-Bardanca, Mónica, López, María, Fernández-Cuenca, Felipe, Oteo-Iglesias, Jesus, Pascual, Álvaro, Martínez-Martínez, Luis, Domingo-Calap, Pilar, Bou, Germán, Tomás, María, Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA), Agencia Estatal de Investigación (España), European Commission, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Red Española de Investigación en Patología Infecciosa, Xunta de Galicia, Axencia Galega de Innovación, European Society of Clinical Microbiology and Infectious Diseases, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Red de Investigación Cooperativa en Investigación en Patología Infecciosa (España), Plan Nacional de I+D+i (España), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, and Xunta de Galicia (España)
- Subjects
0301 basic medicine ,Imipenem ,Klebsiella pneumoniae ,medicine.drug_class ,Mitomycin ,030106 microbiology ,Antibiotics ,Resistance ,Drug repurposing ,Microbial Sensitivity Tests ,Bacteriophage therapy ,beta-Lactamases ,Microbiology ,Persistence ,03 medical and health sciences ,Mechanisms of Resistance ,medicine ,polycyclic compounds ,Humans ,Pharmacology (medical) ,Bacteriophages ,Pathogen ,health care economics and organizations ,Pharmacology ,biology ,Mitomycin C ,Broth microdilution ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,Antimicrobial ,humanities ,Anti-Bacterial Agents ,Klebsiella Infections ,Synergy ,030104 developmental biology ,Infectious Diseases ,Lytic cycle ,medicine.drug - Abstract
Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA) on behalf of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)., Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13. Several clinical K. pneumoniae isolates were characterized, and an imipenem-resistant isolate (harboring OXA-245 β-lactamase) and a persister isolate were selected for study. The mitomycin C and imipenem MICs for both isolates were determined by the broth microdilution method. Time-kill curve data were obtained by optical density at 600 nm (OD600) measurement and CFU enumeration in the presence of each drug alone and with the phage. The frequency of occurrence of mutants resistant to each drug and the combinations was also calculated, and the efficacy of the combination treatments was evaluated using an in vivo infection model (Galleria mellonella). The lytic phage vB_KpnM-VAC13 and mitomycin C had synergistic effects on imipenem-resistant and persister isolates, both in vitro and in vivo. The phage-imipenem combination successfully killed the persisters but not the imipenem-resistant isolate harboring OXA-245 β-lactamase. Interestingly, the combinations decreased the emergence of in vitro resistant mutants of both isolates. Combinations of the lytic phage vB_KpnM-VAC13 with mitomycin C and imipenem were effective against the persister K. pneumoniae isolate. The lytic phage-mitomycin C combination was also effective against imipenem-resistant K. pneumoniae strains harboring OXA-245 β-lactamase., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI; RD16/0016/0001, RD16/0016/0006, and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC; http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López were financially supported by grants IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia), and P. Domingo-Calap was financially supported by the ESCMID Research Grant 20200063.
- Published
- 2021